Titelbild

Advisors

 
Portrait

Ian Hunneyball, PhD

Ian Hunneyball has over 40 years of experience in the pharmaceutical and biotech industry sector, covering all aspects of research and development. Ian is currently Senior Vice President, Programme Management at Evotec AG and acts as a consultant to Topas Therapeutics to advise on all aspects of the company’s development programs. He holds a BSc in medical biochemistry and a PhD in experimental pathology from the University of Birmingham, UK. Ian previously served as Director of Research & Development for BASF Pharma in the UK. Prior to that, he was global Director of Research for Boots Pharmaceuticals.

 
Portrait

Ian Hunneyball, PhD

Ian Hunneyball has over 40 years of experience in the pharmaceutical and biotech industry sector, covering all aspects of research and development. Ian is currently Senior Vice President, Programme Management at Evotec AG and acts as a consultant to Topas Therapeutics to advise on all aspects of the company’s development programs. He holds a BSc in medical biochemistry and a PhD in experimental pathology from the University of Birmingham, UK. Ian previously served as Director of Research & Development for BASF Pharma in the UK. Prior to that, he was global Director of Research for Boots Pharmaceuticals.

 
Portrait

Chris Rundfeldt, PhD, DVM

Chris Rundfeldt has more than 20 years of drug development experience as an independent regulatory toxicologist as well as a drug development and regulatory affairs executive in several biopharmaceutical companies. He previously worked as a drug development/regulatory affairs consultant at Brinker Pharma Consulting and was also Vice President Science and Pre-clinical at Forward Pharma GmbH. He previously served as Head of Clinical Research and Vice President of Pharmacology at elbion AG, a company he co-founded, and was Head of Pharmacology at Arzneimittelwerk Dresden, part of ASTA medica AG. He is a board-certified pharmacologist and toxicologist and received his PhD and DVM from the Tierärztliche Hochschule Hannover, Germany.

 
Portrait

Chris Rundfeldt, PhD, DVM

Chris Rundfeldt has more than 20 years of drug development experience as an independent regulatory toxicologist as well as a drug development and regulatory affairs executive in several biopharmaceutical companies. He previously worked as a drug development/regulatory affairs consultant at Brinker Pharma Consulting and was also Vice President Science and Pre-clinical at Forward Pharma GmbH. He previously served as Head of Clinical Research and Vice President of Pharmacology at elbion AG, a company he co-founded, and was Head of Pharmacology at Arzneimittelwerk Dresden, part of ASTA medica AG. He is a board-certified pharmacologist and toxicologist and received his PhD and DVM from the Tierärztliche Hochschule Hannover, Germany.

 
Portrait

Rupert Sandbrink, MD, PhD

Rupert Sandbrink has over twenty years of clinical development experience spanning all stages from first-in-human studies to product launches, including regulatory and medical affairs, as well as pharmacovigilance. He is currently Chief Medical Officer at Vico Therapeutics B.V., a developer of ribonucleic acid (RNA) modulating therapies. He previously served as Chief Development Officer/Chief Medical Officer at Topas, where he led clinical product development and regulatory affairs. Prior to that, he held senior management positions in clinical development at Forward Pharma A/S and Bayer (previously Schering AG). He received his medical training and his PhD in molecular biology at the University of Heidelberg and is a Board-certified clinical pharmacologist.

 
Portrait

Rupert Sandbrink, MD, PhD

Rupert Sandbrink has over twenty years of clinical development experience spanning all stages from first-in-human studies to product launches, including regulatory and medical affairs, as well as pharmacovigilance. He is currently Chief Medical Officer at Vico Therapeutics B.V., a developer of ribonucleic acid (RNA) modulating therapies. He previously served as Chief Development Officer/Chief Medical Officer at Topas, where he led clinical product development and regulatory affairs. Prior to that, he held senior management positions in clinical development at Forward Pharma A/S and Bayer (previously Schering AG). He received his medical training and his PhD in molecular biology at the University of Heidelberg and is a Board-certified clinical pharmacologist.

 
Portrait

Susanne Wagner, DVM

Susanne Wagner has more than 25 years of experience in nanodrug research and development. Starting at the Dept. of Contrast Media Research at Schering AG, in cooperation with the Institute für Diagnostikforschung GmbH Berlin, she participated in the development of Resovist® and liposomal encapsulated iodinated contrast media with responsibilities in in vivo imaging and safety pharmacology. As a Co-Founder of Ferropharm GmbH, she successfully managed the entire development up to phase II clinical trials of an iron oxide based contrast medium. With this background, she has unique expertise in pre-clinical and clinical development of iron oxide based nanodrugs, including in the areas of physics, chemistry and non-clinical testing, with special focus on regulatory requirements.

 
Portrait

Susanne Wagner, DVM

Susanne Wagner has more than 25 years of experience in nanodrug research and development. Starting at the Dept. of Contrast Media Research at Schering AG, in cooperation with the Institute für Diagnostikforschung GmbH Berlin, she participated in the development of Resovist® and liposomal encapsulated iodinated contrast media with responsibilities in in vivo imaging and safety pharmacology. As a Co-Founder of Ferropharm GmbH, she successfully managed the entire development up to phase II clinical trials of an iron oxide based contrast medium. With this background, she has unique expertise in pre-clinical and clinical development of iron oxide based nanodrugs, including in the areas of physics, chemistry and non-clinical testing, with special focus on regulatory requirements.